About NBR“Nightly Business Report produced by CNBC” (NBR) is an award-winning and highly-respected nightly business news program that airs on public television. Television’s longest-running evening business news broadcast, “NBR” features in-depth coverage and analysis of the biggest financial news stories of the day and access to some of the world’s top business leaders and policy makers.
- U.S. Steel plans to lay off hundreds of workers in Michigan
- China lowers borrowing costs — but UBS says the impact will probably be 'very muted'
- Porsche to stream Apple Music into all-new Taycan EV
- Apple is spending $6 billion on original shows and trying to beat Disney+ to market, reports FT
- A generational shift in consumer tastes is a boon for these retailers, Jim Cramer says
NBR on TwitterMy Tweets
Subscribe to RSS
Biotech & Pharmaceuticals
Shares of drug distributors fell Tuesday after a report said McKesson, Cardinal Health and AmerisourceBergen have proposed paying $10 billion to settle claims they helped to fuel the U.S. opioid epidemic.
The Trump administration outlined on Wednesday a proposal that would allow the U.S. to legally import cheaper prescription drugs from Canada, a tactic the U.S. pharmaceutical industry and regulators have warned could threaten consumer safety.
Drug maker companies Merck and Eli Lilly posted better than expected results in its quarterly earnings reports. Meg Tirrell takes a closer look at both of these big pharmaceutical firms.
President Donald Trump is working on a proposal that would allow the United States to import drugs from Canada, Health and Human Services Secretary Alex Azar told CNBC.
Pfizer will be merging with its off patent business with Mylan creating a new company that controls a number of blockbuster medicines. Meg Tirrell has more for us on this mega deal.
Pfizer, the world’s largest drugmaker, plans to divest its off-patent drug business and combine it with generic-drug maker Mylan.
Senate Finance Committee Chairman Chuck Grassley said Thursday that he wants to include an abandoned White House proposal that would have eliminated rebates from government drug plans in the final version of a bipartisan drug pricing bill.
Meg Tirrell reports on one drug company’s strategy to combat itself from possible liabilities of its oxycodone and hydrocodone pills
Just over a year after buying online pharmacy PillPack for $753 million, Amazon is engaged in a bitter battle with an incumbent player in the pharmacy industry, which sources tell CNBC is working behind the scenes to prevent the company from accessing important patient data.
Johnson & Johnson topped analysts’ expectations and increased its guidance. But, the company is under increased scrutiny and pressure. Meg Tirrell explains why.
Johnson & Johnson vowed to defend itself against lawsuits alleging the company fueled the opioid crisis and that its namesake talc-based baby powder caused ovarian cancer and mesothelioma.
Pharmaceutical giant Johnson & Johnson is set to test an experimental HIV vaccine in the U.S. and Europe sometime this year, the company confirmed with CNBC.
The Trump Administration pulls back its prescription drug rebate rules which sent insurance stocks higher in trading but will big pharma be the next target. Meg Tirrell has more for us.
The Trump administration has withdrawn its proposal to eliminate rebates from government drug plans, a key component of the president’s blueprint to lower prescription drug prices, a White House spokesman confirmed.
President Donald Trump’s executive order on kidney care will be a boon to a transplant diagnostics company, according to Raymond James.